InsidersTradesSigma
Track the CANDEL THERAPEUTICS INC stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €1bn. The latest transaction was disclosed on 29 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: SESHU P TYAGARAJAN. All data is free.
Analysts rate CANDEL THERAPEUTICS INC Strong Buy (bullish), based on 8 analysts. Average price target: US$21.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
CANDEL THERAPEUTICS INC es una empresa centrada en el desarrollo de terapias innovadoras para el tratamiento de enfermedades graves. Cotiza en el NASDAQ bajo el símbolo XNAS.